Eli Lilly has anted up for its next big bet on a next-gen pain drug, buying Hydra assets

礼来将目标转向用于 TRPA -1的新型止痛药,短期内将开展实验

2018-12-18 08:41:23 endpoint News

本文共671个字,阅读需2分钟

With its new CGRP migraine drug Emgality (galcanezumab) OK’d a few months ago and more late-stage work underway on lasmiditan and tanezumab, Eli Lilly’s pain group has selected its next shot at a next-gen drug.  The target is TRPA-1, one of the family of ion channel targets that has long been a focus at Hydra Biosciences, run by Russ Herndon. Hydra at one point had a collaboration on this way back in 2012 with Cubist, just before Cubist got bought out by Merck. What’s the big attraction? First, it’s a non-opioid, which regulators have wanted to encourage in the face of a national epidemic of opioid abuse. But a number of academic investigators, including UCSF’s David Julius, have been attracted to a target that is built in as part of the body’s alarm system for pungent, inflammatory irritants, like wasabi or tear gas. Researchers believe it can also be adapted for chronic pain. Mark Mintun, vice president of pain and neurodegeneration research at Lilly, is buying up all of Hydra’s assets in this area — although he isn’t saying for how much — adding that the plan now is to start clinical trials “in the near term.”  Lilly has been actively hunting up a slate of new deals to beef up its pipeline.  Just a few days ago there was a deal to collaborate with AC Immune on tau for Alzheimer’s, going back into a field where it’s seen nothing but failure. The pharma giant has had its ups and downs in R&D, often coming in late when a new field opens up, but CEO Dan Ricks and new R&D chief Dan Skovronsky are promising to pick up the pace.
几个月前,随着新的 CGRP 偏头痛药物 Emgalizumaty ( Galcanizumab )的问世,以及更多关于拉西坦和坦尼扎马的后期研究, Eli Lilly 的疼痛小组选择了下一次注射的下一代药物。 目标是 TRPA-1,这是一个离子通道的家族目标,长期以来一直是一个重点在 Hydra 生物科学,由 Russ Herndon 运行。Hydra 曾在2012年与 Cubist 合作过,就在 Cubist 被默克收购之前。 最大的吸引力是什么?首先,这是一种非阿片类药物,监管者希望在面对全国范围的阿片类药物滥用时予以鼓励。但包括加州大学旧金山分校( UCSF )的戴维•朱利叶斯( David Julius )在内的许多学术调查人员,都被一个目标吸引了。这个目标是作为人体刺激性、炎症性刺激(如黄蜂或催泪瓦斯)警报系统的一部分而构建的。研究人员相信,它也可以适应慢性疼痛。 礼来公司( Lilly )负责疼痛和神经变性研究的副总裁马克•敏顿( Mark Mintun )正在收购 Hydra 在该领域的所有资产——尽管他没有透露具体金额——他补充说,目前的计划是“在短期内”开始临床试验。这是一个很好的例子 礼来公司一直在积极寻找一系列新的交易,以加强其管道。就在几天前,与 AC Immune 就 tau 治疗阿尔茨海默症达成了一项合作协议,回到了一个只有失败才能看到的领域。这家制药巨头的研发经历了起起起伏伏,往往是在新领域开放的后期,但首席执行官 DanRicks 和新研发总监 DanSkovronsky 承诺加快步伐。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文